Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07476001 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
A Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07476001: Recruiting Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
NCT07476001 is a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 12 participants, below the 198-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07476001, a Phase 2 study of Metastatic Castration-Resistant Prostate Cancer, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer. Participants will be asked to spend about 6 months in this study. Participants will take study drug for 3.5 months.
Primary Outcome
Percentage of patients who can complete 3 doses of Tc400 followed by at least 2 doses of PSMA-617.
Conditions Studied
Interventions
- DRUG Testosterone cypionate (Tc)
- DRUG ADT with Luteinizing hormone-releasing hormone (LHRH) analog
- DRUG PSMA-617
Study Locations (1)
Florida
- Moffitt Cancer Center - Tampa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-03 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT07476001 shows while recruiting
NCT07476001 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 198-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which Testosterone cypionate (Tc) is the first listed.
NCT07476001 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07476001 about?
NCT07476001 is a clinical study titled "Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC". The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer. Participants will be asked to spend about 6 months in this study. Participants will take study drug for 3.5...
What is the current status of trial NCT07476001?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2026-03. Estimated completion is 2027-09.
What conditions does trial NCT07476001 study?
This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer.
What interventions are being tested in trial NCT07476001?
The interventions under investigation include: Testosterone cypionate (Tc) (DRUG), ADT with Luteinizing hormone-releasing hormone (LHRH) analog (DRUG), PSMA-617 (DRUG).
Who is sponsoring clinical trial NCT07476001?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07476001 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Castration-Resistant Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07476001's enrollment target sits among peer trials
12 69th of 69 higher than 1 of 69 other Metastatic Castration-Resistant Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Castration-Resistant Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
RECRUITING · Phase 2
-
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 2
-
Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
RECRUITING · Phase 2
-
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 2
-
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia